AMENDMENT TO THE SPECIFICATION

Please amend the specification as follows, without prejudice or disclaimer.

Please replace paragraph [0008] with the following amended paragraph:

[0008] **FIG. 1:** High-dose IFN-α recalls tumor-reactive T cells previously activated by vaccines. PBMC from patients M166 ~~AND~~ and M335 were stimulated with the mixture of HLA-A*0201 binding gp100 peptides (gp100:209-2M and gp100:280-9V) for 8 days as described in the materials and methods. The cells were then stained with the respective phycoerythrin-labeled tetramers and CD8-FITC antibodies and analyzed by flow cytometry. The percentage of $CD8^+$tetramer$^+$ cells, representing gp100-reactive T cells, was then determined and is indicated in the box in each dot-plot. Before starting the schedule of vaccinations, very few gp100-reactive T cells were found in both patients (baseline). Both patients responded to vaccination and the peak response is shown in the dot-plot marked "on vaccine". Before commencing HDI, gp100-reactive T cell numbers had essentially returned to baseline (follow-up). Two weeks (for M166) and 3 weeks (for M335) after starting HDI, the number of gp100-reactive T cells again increased. All cultures were carried out at the same time, using blood that had been obtained at the indicated times and then cryopreserved.

Please replace paragraph [0083] with the following amended paragraph:

[0083] Treatment with HDI: IFN~~γ~~α2b (Schering Canada, Pointe-Claire, Quebec) was administered using the dose and schedule previously tested. (Kirkwood,et al. 1996. *J.Clin.Oncol.* 14, 7-17) HDI consisted of 20 MU/m^2/d IV 5 days/week×4 weeks. The IFNα2b dose was held and then restarted at a 33% dose reduction if severe toxicity (grade 3 or 4, defined by the common toxicity criteria established by the National Cancer Institute Cancer Treatment Evaluation Program; Kirkwood, et al. 2001. *J.Clin.Oncol.* 19, 2370-2380) was observed. A second decrease of 33% of the original dosage was made in some patients for recurrent severe toxicity.